Related Experiment Videos
GABA-agonist therapy for Alzheimer's disease
Clinical Neuropharmacology
|January 1, 1986
Summary
This study investigated if stimulating gamma-aminobutyric acid (GABA) pathways with THIP could improve cognitive function in Alzheimer's disease patients. Results showed no significant cognitive improvement, suggesting GABA system deficits may not drive Alzheimer's dementia.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Reduced cerebral gamma-aminobutyric acid (GABA) neurons are implicated in Alzheimer's disease (AD).
- GABA system dysfunction may contribute to the cognitive decline observed in AD.
Purpose of the Study:
- To evaluate the therapeutic potential of a GABA agonist, THIP, in improving cognitive function in Alzheimer's disease patients.
- To assess the role of GABA system dysfunction in the intellectual decline associated with AD.
Main Methods:
- A controlled therapeutic trial involving six Alzheimer's patients with mild to moderate dementia.
- Administration of THIP (a potent GABA agonist) at maximum tolerated dosage.
- Assessment of cognitive function and adverse effects.
Main Results:
- No significant changes in cognitive function were observed in patients treated with THIP.
- Centrally mediated adverse effects, similar to other GABA agonists, were noted at higher doses.
- The study did not demonstrate a therapeutic benefit of stimulating GABA-mediated synaptic function.
Conclusions:
- Pharmacologic stimulation of central GABA pathways may not be a beneficial treatment strategy for Alzheimer's disease.
- A deficit in the GABA system may not be the primary determinant of dementia in Alzheimer's disease.